JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 46, 2015, Pages E6301-E6310

  Xu, Ming ^a   Tchkonia, Tamara ^a   Ding, Husheng ^a   Ogrodnik, Mikolaj ^a,b   Lubbers, Ellen R ^a   Pirtskhalava, Tamar ^a   White, Thomas A ^a   Johnson, Kurt O ^a   Stout, Michael B ^a   Mezera, Vojtech ^a   Giorgadze, Nino ^a   Jensen, Michael D ^a   LeBrasseur, Nathan K ^a   Kirkland, James L ^a  

^a MAYO CLINIC   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cellular senescence; Frailty; Interleukin 6; Jak stat pathway; Ruxolitinib

Indexed keywords

CXCL1 CHEMOKINE; EOTAXIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE H2AX; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; JANUS KINASE INHIBITOR; KI 67 ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; RANTES; SMALL INTERFERING RNA; STAT3 PROTEIN;

ADIPOSE DERIVED STEM CELL; ADIPOSE TISSUE; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL AGING; CELL PROLIFERATION; CONDITIONED MEDIUM; CONTROLLED STUDY; CYTOKINE RELEASE; ENDURANCE; FOOD INTAKE; GRIP STRENGTH; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE MIGRATION; MALE; MONOCYTE; MOUSE; MUSCLE STRENGTH; NONHUMAN; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; SENESCENCE ASSOCIATED SECRETORY PHENOTYPE; SIGNAL TRANSDUCTION; ADIPOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; EXTRACELLULAR MATRIX; GENETICS; MACROPHAGE; METABOLISM; UMBILICAL VEIN ENDOTHELIAL CELL;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; CELL AGING; CELL MOVEMENT; EXTRACELLULAR MATRIX; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; JANUS KINASES; MACROPHAGES; MICE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84966397603     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1515386112     Document Type: Article

References (67)

1. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL (2013) Cellular senescence and the senescent secretory phenotype: Therapeutic opportunities. J Clin Invest 123(3): 966-972.
2. Michaud M, et al. (2013) Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc 14(12):877-882.
3. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153(6):1194-1217.
4. Harris TB, et al. (1999) Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106(5):506-512.
5. Bruunsgaard H, Andersen-Ranberg K, Hjelmborg Jv, Pedersen BK, Jeune B (2003) Elevated levels of tumor necrosis factor alpha and mortality in centenarians. Am J Med 115(4):278-283.
6. Pai JK, et al. (2004) Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351(25):2599-2610.
7. Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med 71(2):171-186.
8. Schetter AJ, Heegaard NH, Harris CC (2010) Inflammation and cancer: Interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 31(1):37-49.
9. Spranger J, et al. (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52(3):812-817.
10. McGeer PL, McGeer EG (2004) Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci 1035:104-116.
11. McGeer PL, McGeer EG (2004) Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10(Suppl 1):S3-S7.
12. Campisi J, d'Adda di Fagagna F (2007) Cellular senescence: When bad things happen to good cells. Nat Rev Mol Cell Biol 8(9):729-740.
13. Dimri GP, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92(20):9363-9367.
14. Jeyapalan JC, Ferreira M, Sedivy JM, Herbig U (2007) Accumulation of senescent cells in mitotic tissue of aging primates. Mech Ageing Dev 128(1):36-44.
15. Paradis V, et al. (2001) Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum Pathol 32(3):327-332.
16. Wang C, et al. (2009) DNA damage response and cellular senescence in tissues of aging mice. Aging Cell 8(3):311-323.
17. Melk A, et al. (2003) Cell senescence in rat kidneys in vivo increases with growth and age despite lack of telomere shortening. Kidney Int 63(6):2134-2143.
18. Erusalimsky JD, Kurz DJ (2005) Cellular senescence in vivo: Its relevance in ageing and cardiovascular disease. Exp Gerontol 40(8-9):634-642.
19. Coppé JP, et al. (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6(12):2853-2868.
20. Coppé JP, et al. (2010) A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS One 5(2):e9188.
21. Baker DJ, et al. (2011) Clearance of p16Ink4a-positive senescent cells delays ageingassociated disorders. Nature 479(7372):232-236.
22. Zhu Y, et al. (2015) The Achilles' heel of senescent cells: From transcriptome to senolytic drugs. Aging Cell 14(4):644-658.
23. Meyer SC, Levine RL (2014) Molecular pathways: Molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res 20(8):2051-2059.
24. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9(11):798-809.
25. Richard AJ, Stephens JM (2011) Emerging roles of JAK-STAT signaling pathways in adipocytes. Trends Endocrinol Metab 22(8):325-332.
26. Rane SG, Reddy EP (1994) JAK3: A novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 9(8):2415-2423.
27. Ghoreschi K, Laurence A, O'Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228(1):273-287.
28. Russell SM, et al. (1995) Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science270(5237):797-800.
29. Nosaka T, et al. (1995) Defective lymphoid development in mice lacking Jak3. Science 270(5237):800-802.
30. Karaghiosoff M, et al. (2000) Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13(4):549-560.
31. Shimoda K, et al. (2000) Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 13(4):561-571.
32. Harrison C, et al. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787-798.
33. Verstovsek S, et al. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799-807.
34. Pardanani A, et al. (2013) Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 27(6):1322-1327.
35. Fridman JS, et al. (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: Preclinical characterization of INCB028050. J Immunol 184(9): 5298-5307.
36. Ghoreschi K, et al. (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186(7):4234-4243.
37. Toso A, et al. (2014) Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Reports 9(1):75-89.
38. Tchkonia T, et al. (2013) Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab 17(5):644-656.
39. Tchkonia T, et al. (2010) Fat tissue, aging, and cellular senescence. Aging Cell 9(5): 667-684.
40. Stout MB, et al. (2014) Growth hormone action predicts age-related white adipose tissue dysfunction and senescent cell burden in mice. Aging (Albany, NY) 6(7):575-586.
41. Lumeng CN, et al. (2011) Aging is associated with an increase in T cells and inflammatory macrophages in visceral adipose tissue. J Immunol 187(12):6208-6216.
42. Villaret A, et al. (2010) Adipose tissue endothelial cells from obese human subjects: Differences among depots in angiogenic, metabolic, and inflammatory gene expression and cellular senescence. Diabetes 59(11):2755-2763.
43. Dauer DJ, et al. (2005) Stat3 regulates genes common to both wound healing and cancer. Oncogene 24(21):3397-3408.
44. Wu D, et al. (2007) Aging up-regulates expression of inflammatory mediators in mouse adipose tissue. J Immunol 179(7):4829-4839.
45. Starr ME, Evers BM, Saito H (2009) Age-associated increase in cytokine production during systemic inflammation: Adipose tissue as a major source of IL-6. J Gerontol A Biol Sci Med Sci 64(7):723-730.
46. Fried LP, et al.; Cardiovascular Health Study Collaborative Research Group (2001) Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146-M156.
47. Ferrucci L, et al. (1999) Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 47(6):639-646.
48. Reuben DB, et al. (2002) Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. JAm Geriatr Soc 50(4):638-644.
49. Cohen HJ, Pieper CF, Harris T, Rao KM, Currie MS (1997) The association of plasma IL-6levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci 52(4):M201-M208.
50. Reuben DB, Judd-Hamilton L, Harris TB, Seeman TE; MacArthur Studies of Successful Aging (2003) The associations between physical activity and inflammatory markers in high-functioning older persons: MacArthur Studies of Successful Aging. J Am Geriatr Soc 51(8):1125-1130.
51. Whitehead JC, et al. (2014) A clinical frailty index in aging mice: Comparisons with frailty index data in humans. J Gerontol A Biol Sci Med Sci 69(6):621-632.
52. Grunnet L, Poulsen P, Klarlund Pedersen B, Mandrup-Poulsen T, Vaag A (2006) Plasma cytokine levels in young and elderly twins: Genes versus environment and relation to in vivo insulin action. Diabetologia 49(2):343-350.
53. Shaw AC, Goldstein DR, Montgomery RR (2013) Age-dependent dysregulation of innate immunity. Nat Rev Immunol 13(12):875-887.
54. Chung HY, et al. (2009) Molecular inflammation: Underpinnings of aging and agerelated diseases. Ageing Res Rev 8(1):18-30.
55. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
56. Coppé JP, Desprez PY, Krtolica A, Campisi J (2010) The senescence-associated secretory phenotype: The dark side of tumor suppression. Annu Rev Pathol 5:99-118.
57. Laberge RM, et al. (2012) Glucocorticoids suppress selected components of the senescence-associated secretory phenotype. Aging Cell 11(4):569-578.
58. Moiseeva O, et al. (2013) Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NFκB activation. Aging Cell 12(3):489-498.
59. Laberge RM, et al. (2015) MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol 17(8):1049-1061.
60. Tefferi A, Litzow MR, Pardanani A (2011) Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365(15):1455-1457.
61. Heinrich PC, et al. (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374(Pt 1):1-20.
62. Kuilman T, et al. (2008) Oncogene-induced senescence relayed by an interleukindependent inflammatory network. Cell 133(6):1019-1031.
63. Verstovsek S, et al. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117-1127.
64. Quintás-Cardama A, et al. (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115(15):3109-3117.
65. Tchkonia T, et al. (2005) Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots. Am J Physiol Endocrinol Metab 288(1):E267-E277.
66. Cartwright MJ, et al. (2010) Aging, depot origin, and preadipocyte gene expression. J Gerontol A Biol Sci Med Sci 65(3):242-251.
67. Lee BY, et al. (2006) Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 5(2):187-195.